Category Archives: Other

Sinocare and EoFlow Diabetes Tech Collaboration; Provention Announces Positive Interim Results for Ph1 PROVENT Trial; Dario Partners with Virgin Pulse; Teva and Adocia Q3 ’21 Earnings Updates

A series of cardiometabolic-related news items have been observed: Sinocare announced it intends to invest $7.9M in EOFlow to combine Sinocare’s sensors with EOFlow pumps in China; Provention Bio announced positive interim results for its PRV-101 vaccine trial (PROVENT); Dario announced a partnership with Virgin Pulse; Teva (press release; slides) hosted its Q3 ’21 earnings call; and Adocia issued a press release for its Q3 ’21 earnings. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Lilly and Novartis Q3 ’21 Earnings Updates

Today, Lilly (press release; slides) and Novartis (press release; slides) hosted their Q3 ’21 earnings calls. Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Apple Watch 8 Reportedly Set to Include BGM; Lifescan Launches OneTouch Solutions; Xeris and Merck Collaboration; Dario Partners with New Employer Group; Tidepool Period Project Receives Financial Support

A series of cardiometabolic-related news items have been observed: New reports suggest the Apple Watch Series 8 may include a blood glucose reader (view article); Lifescan announced the launch of OneTouch Solutions; Xeris announced a collaboration agreement with Merck to leverage Xeris’s injection suspension technology “for the purpose of engineering ultra-high concentration, ready-to-use [mAb] formulations”; Dario announced a new agreement with a US national employer; and Tidepool announced it has received financial support from Amazon Web Services (AWS) for Tidepool Period Project. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Metacrine Discontinues NASH Program; Ikenna Ogbaa Joins GSK to Lead Daprodustat Medical Team; Biocon CY Q3 ’21 (FY Q2 ’22) Earnings Update; Integrity Applications Hires New President and COO

A series of cardiometabolic-related news items have been observed: Metcarine announced it is discontinuing its NASH FXR development program following Ph2a interim results; Ikenna Ogbaa, MD joins GSK to lead daprodustat US medical affairs (view LinkedIn profile); Biocon hosted its Q3 ’21 (FY Q2 ’22) earnings call (press release); and Integrity Applications announced Dr. Paul V. Goode (view LinkedIn) will join the company as the new President and COO. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Viatris’ Semglee Preferred on Express Scripts NPF; DreaMed’s Advisor Pro Launched in Leading Children’s Hospital; MiniMed 780G & Guardian 3 TIR In Pediatrics Comparable to Adults; Abbott and Roche Q3 ’21 Earnings Updates; vTv Therapeutics Hires New President and CEO; Adhera Adds Target Indications for MLR-1023

A series of cardiometabolic-related news items have been observed from Viatris, DreaMed, Medtronic, Abbott, Roche, vTv Therapeutics, and Adhera Therapeutics. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Lilly’s Ph3 Tirzepatide SURPASS-4 Results Published in Lancet; FDA Pre-Submission for rt-Glucose Salivary Test; Ultrahuman Hires Chief Business Officer; J&J Q3 ‘21 Earnings Update

A series of cardiometabolic-related news items have been observed: Lilly announced results of its Ph3 SURPASS-4 trial comparing tirzepatide to insulin glargine in patients with T2DM and an increased CV risk were published in The Lancet (view publication); IQ Group Global announced that GBS Inc has filed a pre-submission package with FDA for its salivary glucose test; Ultrahuman announced Bhuvan Srinivasan will join the company as its first chief business officer; and J&J hosted its Q3 ’21 earnings call (press release; slides). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Medtronic to Acquire Triple Jump?; Esperion to Reduce Workforce by 40%; Diamyd’s Ph3 T1DM Vaccine Trial Initiated; Vertex Announces Positive Results From Ph1/2 VX-880 Trial

A series of cardiometabolic-related news items have been observed: It has been reported that Medtronic is in advanced discussions to acquire a patch pump company (view article); Esperion announced plans to align operational and expense structure, including a workforce reduction of 40%; Diamyd announced the initiation of its Ph3 T1DM Vaccine trial (DIAGNODE-3) in Europe; and Vertex announced positive results from the first patient in Ph1/2 VX-880 trial for patients with T1DM. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Forxiga Pediatric Indication and Generic Sitagliptin Receive Positive CHMP Opinions

Two cardiometabolic-related news items have been observed: AstraZeneca’s Forxiga received a positive CHMP opinion to include treatment of children aged 10 years and older with T2DM; and generic sitagliptin received a positive CHMP opinion. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

G&L Bs-glargine Completes Ph3; Adocia’s BC Lispro Cleared for Pivotal Ph3 in China; Dario Signs National Digital Behavioral Health Contract

A series of cardiometabolic-related news items have been observed: Gan & Lee announced the conclusion of its two Ph3 bs-glargine studies; Adocia announced that its partner, Tonghua Dongbao, received clearance to initiate a Ph3 trial for uRAI BioChaperone Lispro in China; and Dario announced it was selected as the digital behavioral health provider for an undisclosed US national health plan. Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.

Jardiance HFpEF Indication Filed in EU; Generic Sitagliptin (EMEA/H/C/005741) CHMP Decision?; October 11-14 CHMP Agenda

The CHMP agenda for this month (October 11-14) has been released, and it includes two notable items, BI/Lilly has filed the Jardiance HFpEF indication and an opinion for generic sitagliptin (EMEA/H/C/005741) is up for adoption. Below, FENIX provides highlights and insights from the October 2021 CHMP agenda.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.